LAUSR

disease, compared to only 14% in the dual-ICI arm. This is particularly important for this trial because only intrahepatic disease was irradiated. Furthermore, the maximum GTV was mostly restricted to 100 cc and in the case of multiple lesions, the RT target was left to investigator discretion. This means that the fraction of tumor burden irradiated in these patients varied widely and was lower in the patients in the nivolumab arm, as half of them had extrahepatic metastases, which by design, were not included in the target volume. This is an important distinction, and crucial for two reasons.